Skip to content

Clinical Study of Breast Conserving Surgery Combined With Intraoperative Radiotherapy for Early Breast Cancer

Clinical Study of Breast Conserving Surgery Combined With Intraoperative Radiotherapy for Early Breast Cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06375798
Enrollment
620
Registered
2024-04-19
Start date
2020-11-19
Completion date
2026-11-19
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, HER2-negative Breast Cancer

Keywords

Breast preservation surgery, Breast cancer invasion, radiotherapy

Brief summary

A Single-center, open, prospective study,for analyzing the local recurrence rate, the incidence of incision complications and the aesthetic effect of intraoperative radiotherapy in early breast cancer patients after breast-conserving surgery.

Detailed description

This is a single-center, open, prospective study. A total of 620 breast cancer patients meeting the exclusion criteria were included and assigned to the IORT group and the WBI group according to the patients' wishes. The IORT group received intraoperative radiotherapy with a regimen of 50-KF-x 20Gy/1f, and the WBI group received whole milk external irradiation with a regimen of 50Gy/25f. If the postoperative paraffin pathology of patients in the IORT group indicated positive axillary lymph nodes, the radiologist should determine whether to irradiate the whole milk and lymph nodes in the drainage area. If the postoperative pathology of patients in the WBI group indicated the need for chemotherapy, radiotherapy was initiated within 6 weeks after the end of chemotherapy, allowing both endocrine therapy and radiotherapy to be performed simultaneously. The clinical standard treatment regimen (chemotherapy, endocrine therapy, etc.) was developed based on postoperative pathological and immunohistochemical reports.

Interventions

PROCEDUREradiotherapy

If the postoperative paraffin pathology of patients in the IORT group indicated positive axillary lymph nodes, the radiologist should determine whether to irradiate the whole milk and lymph nodes in the drainage area.If the postoperative pathology of patients in the WBI group indicated the need for chemotherapy, radiotherapy was initiated within 6 weeks after the end of chemotherapy, allowing both endocrine therapy and radiotherapy to be performed simultaneously. Clinical standard treatment plan (chemotherapy, endocrine therapy, etc.) was developed based on postoperative pathological and immunohistochemical reports.

Sponsors

Hebei Medical University Fourth Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
55 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Age ≥55 years old; 2. Cytology or histology confirmed invasive breast cancer or intraductal carcinoma in situ (DCIS) with a clinical stage of Tis-1N0M0; 3. Patients who are willing to preserve milk and intend to undergo breast-conserving surgery; 4. If invasive breast cancer is confirmed, the surgical margin negative ≥2mm should be met. If DCIS is confirmed, the surgical margin should be negative ≥3mm; 5. ER≥ 30% and PR≥ 1%, HER2 negative; 6. Voluntary participation in this study, signed informed consent, good compliance, cooperate with follow-up.

Exclusion criteria

1. Simultaneous diagnosis of bilateral or multifocal breast cancer; 2. Previous ipsilateral breast cancer and/or prior chest wall radiation therapy; 3. There are active connective tissue diseases such as scleroderma and systemic lupus erythematosus in the chest; 4. The investigators did not consider the patient suitable for participation in any other conditions of the study.

Design outcomes

Primary

MeasureTime frameDescription
LRFSAt least 5 yearsThere was no local recurrence survival

Countries

China

Contacts

Primary Contactcuizhi GENG, archiater
gengcuizhi@hotmail.com135 0321 6325
Backup Contactmeiqi WANG, attending
maggie92320@hotmail.com186 3305 1639

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026